Shots:

• The first two patients have been enrolled in EU P-IIb/II clinical trial to evaluate the safety, PoC, and dosing of AMT-130 in patients with Huntington’s disease at multiple sites in Poland, UK & Germany
• The patient enrollment is expected to be complete at the end of 2022. Additionally, the company provides the safety and target-engagement data from 10 patient, low-dose cohort in the US trial in Q2’22
• The study consists of an initial 6mos. post-treatment study period based on long-term follow-up for 5yrs. The study is currently open for recruitment at IPiN and surgery at INC in Poland and is expected to expand in the UK & Germany

Ref: Globe Newswire | Image: The Street